Futura Medical (FUM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

14.65p
   
  • Change Today:
    -0.100p
  • 52 Week High: 47.50
  • 52 Week Low: 7.75
  • Currency: UK Pounds
  • Shares Issued: 245.63m
  • Volume: 320,338
  • Market Cap: £35.98m
  • RiskGrade: 532

Futura Medical recruits 1,000 patients for erectile treatment trial

By Josh White

Date: Wednesday 19 Jun 2019

LONDON (ShareCast) - (Sharecast News) - Pharmaceutical company Futura Medical announced the completion of patient recruitment for the first European phase 3 study of MED2005, 'FM57', on Wednesday, adding that it remained on track to deliver headline data by the end of 2019.
The AIM-traded firm said FM57 had completed recruitment of more than 1,000 patients in the study for the treatment of mild, moderate and severe erectile dysfunction.

It said the study included around 60 centres across central and eastern Europe, and would compare the efficacy of 0.2%, 0.4% and 0.6% GTN doses of MED2005 against that of placebo, with an initial three-month study period for each patient.

FM57's protocol incorporated feedback received from key opinion leaders in erectile dysfunction, the US and EU regulatory agencies, as well as potential commercial partners, to increase the chances of regulatory approval as well as optimising the commercial value.

"We are extremely pleased to complete recruitment of over 1,000 patients for the first European Phase 3 study, 'FM57', of MED2005, within our expected timelines and budget and I would like to thank all parties involved in reaching this important milestone," said Futura Medical chief executive officer James Barder.

"The company's focus is now on the Phase 3 data read-out at the end of the year, which we hope will significantly clinically de-risk MED2005, and help provide commercial partners with greater certainty around the potential opportunity it presents."

Futura Medical said the potential market for such a product was "large", with potential peak sales in excess of $1bn.

It said that if MED2005 was approved, there was an estimated $560m prescription-only market potential, and an estimated incremental $660m+ market potential as an over-the-counter product, in markets where such a move was possible.

The company said its main focus was to deliver phase 3 double-blind headline data by the end of 2019, given it remained a "key value inflection point" for the firm, with the firm continuing discussions with a number of interested commercial partners for the out-licensing of MED2005.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Futura Medical Market Data

Currency UK Pounds
Share Price 14.65p
Change Today -0.100p
% Change -0.68 %
52 Week High 47.50
52 Week Low 7.75
Volume 320,338
Shares Issued 245.63m
Market Cap £35.98m
RiskGrade 532

Futura Medical Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
49.01% below the market average49.01% below the market average49.01% below the market average49.01% below the market average49.01% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Price Trend
26.44% below the market average26.44% below the market average26.44% below the market average26.44% below the market average26.44% below the market average
50.88% below the sector average50.88% below the sector average50.88% below the sector average50.88% below the sector average50.88% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Futura Medical Dividends

No dividends found

Trades for 03-Jul-2020

Time Volume / Share Price
11:39 10,000 @ 14.49p
11:37 66,613 @ 15.00p
11:31 970 @ 14.49p
11:28 68,910 @ 14.50p
11:27 10,000 @ 14.45p

Futura Medical Key Personnel

CEO James Henry Barder
Finance Director Angela Hildreth

Top of Page